Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEMASURE (HMSR) - Buyout in the works? -- Ignore unavailable to you. Want to Upgrade?

To: bruce bell who wrote (71)	5/4/1999 8:00:00 AM
From: RRICH4	Read Replies (1) \| Respond to of 88

Big Daddy invests in HMSR.... Sweden's Gambro Invests $9 Million in HemaSure of the U.S. Stockholm, May 4 (Bloomberg) -- Gambro AB, the world's second-largest provider of dialysis services, said it invested $9 million in HemaSure Inc., a Marlborough, Massachusetts-based maker of filtration technologies to process blood, to get access to new blood-treatment technologies. Gambro acquired 4.5 million shares, or 30 percent of the company, and may buy stock for an additional $3 million between August 1999 and May 2000. Gambro will also get representation on HemaSure's boards and committees, and COBE BCT, a U.S. unit of Gambro, has expanded its distribution agreement with HemaSure. ''The r\LS filter system produced by HemaSure is an excellent addition to our product offerings for our transfusion medicine customers,'' said Ed Wood, chief executive of COBE BCT, in a statement. Gambro specializes in providing products and clinics for patients who need to get their blood cleaned because they suffer from kidney disease. Gambro currently uses a centrifugal technology, while HemaSure develops filtration technologies. Separately, HemaSure and COBE said they filed a lawsuit in federal court in Denver to seek confirmation that a filter produced by HemaSure and which will be distributed by COBE doesn't infringe patents held by East Hills, New York-based Pall Corp., which has complained that HemaSure has violated its patents. Shares in Gambro rose 1.5 kronor, or 1.7 percent, to 90.5 ($10.7). NYSE/AMEX delayed 20 min. NASDAQ delayed 15 min. Access More Information and Services Above ©1999 Bloomberg L.P. All rights reserved. Terms of Service, Privacy Policy and Trademarks.